SCHEMBL839475

SCHEMBL839475

[CH2]CCc1ccc(OC)c(OC)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.66
KDM4E B2RXH2 1/20 0.66
CA2 P00918 1/20 0.63
POLB P06746 1/20 0.61
CYP19A1 P11511 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
CYP2D6 P10635 1/20 0.61
BLM P54132 1/20 0.59
PMP22 Q01453 1/20 0.59
ALDH1A1 P00352 1/20 0.58
PPARG P37231 1/20 0.58
PPARD Q03181 1/20 0.58
PPARA Q07869 1/20 0.58
AOC3 Q16853 1/20 0.58
STAT3 P40763 1/20 0.56
MAPT P10636 1/20 0.54
ABCB1 P08183 1/20 0.54
HSP90AA1 P07900 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160654 0.88 ATM (0.61) ATMKDM4ECA2POLBCYP19A1
SCHEMBL11044914 0.87 CALM1 (0.67) ATMKDM4ECA2POLBCYP19A1
SCHEMBL16641094 0.87 CYP19A1 (0.77) ATMKDM4ECA2POLBCYP19A1
SCHEMBL31157848 0.87 CYP19A1 (0.77) ATMKDM4ECA2POLBCYP19A1
SCHEMBL7186374 0.86 ATM (0.59) ATMKDM4ECA2POLBCYP19A1
SCHEMBL7191665 0.85 ATM (0.58) ATMKDM4ECA2POLBCYP19A1
SCHEMBL10335393 0.85 CYP19A1 (0.81) ATMKDM4ECA2POLBCYP19A1
SCHEMBL10343404 0.83 ATM (0.70) ATMKDM4ECA2POLBCYP19A1
SCHEMBL30869991 0.83 ATM (0.70) ATMKDM4ECA2POLBCYP19A1
SCHEMBL217601 0.83 CA2 (0.68) ATMKDM4ECA2POLBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207253-A1 Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2024-06-27 US claimed
WO-2022245951-A1 INHIBITORS OF CDR1 FOR REVERSAL OF AZOLE DRUG RESISTANCE IN FUNGAL INFECTIONS UNM RAINFOREST INNOVATIONS (US) 2022-11-24 WO claimed
CN-110563602-A rosmarinic acid derivatives, and preparation method and application thereof 南宁多灵生物科技有限公司 2019-12-13 CN claimed
CN-101821246-B Tetrazole-substituted arylamide derivatives and uses thereof HOFFMANN LA ROCHE 2013-05-01 CN claimed
CN-101500994-B 1,3-disubstituted 4-methyl-1h-pyrrole-2-carboxamides and their use for the manufacture of medicaments GRUENENTHAL GMBH 2012-12-12 CN claimed
CN-101821246-A Tetrazole-substituted arylamide derivatives and uses thereof HOFFMANN LA ROCHE 2010-09-01 CN claimed
EP-1626043-B1 Heterocyclic thioesters MGI GP INC (US) 2007-12-12 EP claimed
EP-1626043-A1 Heterocyclic thioesters MGI GP, Inc. (US) 2006-02-15 EP claimed
US-20050059693-A1 Heterocyclic thioester and ketone hair growth compositions and uses GPI NIL HOLDINGS, INC. 2005-03-17 US claimed
US-6818643-B1 3,9-DIAZABICYCLO(3.3.1)NONAN-2-ONE DERIVATIVES; PEPTIDYL-PROLYL ISOMERASE (PPIASE OR ROTAMASE) INHIBITORS; NEUROPROTECTIVE AGENTS BRISTOL-MYERS SQUIBB COMPANY 2004-11-16 US claimed
US-5976894-A FOR SCREENING BIOASSAYS TO DISCOVER BIOLOGICALLY ACTIVE MEMBERS PHARMACOPEIA, INC. (US) 1999-11-02 US claimed
EP-0700383-B1 NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS SYNTEX INC (US) 1998-09-23 EP claimed
WO-1998034113-A1 COMBINATORIAL LIBRARIES OF BICYCLIC GUANIDINE DERIVATIVES AND COMPOUNDS THEREIN TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO claimed
US-5786448-A FOR SCREENING, SYNTHESIZING PEPTIDE DERIVATIVES TREGA BIOSCIENCES, INC. (US) 1998-07-28 US claimed
US-5763458-A NERVOUS SYSTEM DISORDERS, ANXIETY, ANTIDEPRESSANTS AND COGNITION ACTIVATORS SYNTEX (U.S.A.) INC. (US) 1998-06-09 US claimed
WO-1998019693-A1 COMBINATORIAL LIBRARIES OF CYCLIC UREA AND CYCLIC THIOUREA DERIVATIVES AND COMPOUNDS THEREIN TREGA BIOSCIENCES, INC. (US) 1998-05-14 WO claimed
EP-0700383-A1 NOVEL 1-PHENYLALKANONE 5-HT 4? RECEPTOR LIGANDS SYNTEX (U.S.A.) INC. (US) 1996-03-13 EP claimed
WO-1994027965-A1 NOVEL 1-PHENYLALKANONE 5-HT4 RECEPTOR LIGANDS SYNTEX (U.S.A.) INC. (US) 1994-12-08 WO claimed
EP-0131509-A2 Photographic element containing a polymeric mordant comprising quaternized vinylimidazole and acrylonitrile recurring units EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-01-16 EP claimed
US-4450224-A CATIONIC IMIDAZOLE-CONTAINING VINYL POLYMERS FOR SILVER HALIDE COLOR FILMS EASTMAN KODAK COMPANY (US) 1984-05-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059693-A1 Heterocyclic thioester and ketone hair growth compositions and uses ACOT7, HSD17B7, ZDHHC7 ATM 4562/4885KDM4E 485/4885CA2 2928/4885
US-20240207253-A1 Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections ABCC1, ABCC2, ERG28 ATM 3188/4885KDM4E 3201/4885CA2 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.